Zacks Investment Research·Jun 26, 2026
Here's Why You Should Add Kiniksa Stock to Your Portfolio NowKNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipeline reinforce Kiniksa's growth strategy.
Kiniksa Pharmaceuticals, Ltd.(KNSA)Earnings, Financials & Key Ratios
KNSA•NASDAQ
$62.88
83.8× P/E·Price updated Jul 2, 2026
AboutKiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.Show more
- Revenue$678M+60.1%
- EBITDA$79M+279.4%
- Net Income$59M+236.6%
- EPS (Diluted)0.75+225.0%
- Gross Margin54.63%-36.2%
- EBITDA Margin11.63%+212.0%
- Operating Margin11.4%+205.7%
- Net Margin8.71%+185.3%
- ROE11.73%+219.1%
KNSA Price & Volume
Kiniksa Pharmaceuticals, Ltd. (KNSA) stock price & volume — 10-year historical chart
Loading chart...
Kiniksa Achieves Scalable Growth Through ARCALYST Commercialization
Investment Thesis • Updated 2026Q1
VerdictPositive
Growth:Accelerating
Profitability:Moderate
Financial:Healthy
Cash Flow:Robust
Primary Risk:Single-Asset Revenue Dependency
Key Thesis Takeaways
- Kiniksa has successfully transitioned to a profitable commercial-stage entity, evidenced by 55.5% year-over-year revenue growth in 2026Q1 and the achievement of a 13.7% operating margin.
- While the company benefits from a robust balance sheet with a 3.79 current ratio and minimal debt, its long-term outlook remains tethered to the performance of its single-asset ARCALYST franchise.
- Investors should monitor the sustainability of these margins given the profit-sharing obligations with Regeneron and the inherent risks associated with a lack of diversified revenue streams.
Verdict Logic
the company demonstrates strong fundamental momentum with 55.5% revenue growth and a robust 23.4% free cash flow margin, though investors should remain cautious regarding the single-asset dependency.
KNSA Growth Metrics
Kiniksa Pharmaceuticals, Ltd. (KNSA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years45.45%
TTM56.71%
Profit CAGR
10 Years-
5 Years-
3 Years-31.47%
TTM531.02%
EPS CAGR
10 Years-
5 Years-
3 Years-33.93%
TTM471.43%
Return on Capital
10 Years-45.46%
5 Years-12.03%
3 Years-0.48%
Last Year13.98%
KNSA Recent Earnings
Kiniksa Pharmaceuticals, Ltd. (KNSA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Apr 28, 2026Metric
Actual
Est
EPS
$0.27+50.0%
$0.18
Rev
$214M+4.0%
$206M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.17-41.4%
$0.29
Rev
$202M+0.7%
$201M
Q4 2025
Oct 28, 2025Metric
Actual
Est
EPS
$0.23-30.3%
$0.33
Rev
$181M-8.2%
$197M
Q3 2025
Jul 29, 2025Metric
Actual
Est
EPS
$0.23+27.8%
$0.18
Rev
$157M-5.8%
$166M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.27vs $0.18+50.0% | $214Mvs $206M+4.0% |
| Q1 2026 | Feb 24, 2026 | $0.17vs $0.29-41.4% | $202Mvs $201M+0.7% |
| Q4 2025 | Oct 28, 2025 | $0.23vs $0.33-30.3% | $181Mvs $197M-8.2% |
| Q3 2025 | Jul 29, 2025 | $0.23vs $0.18+27.8% | $157Mvs $166M-5.8% |
Based on last 12 quarters of dataView full earnings history →
Latest KNSA News
Recent stock market news and headlines for Kiniksa Pharmaceuticals, Ltd. (KNSA)
GuruFocus·Jun 22, 2026
Is Kiniksa Pharmaceuticals International PLC (KNSA) Overvalued After 3.5% Rally? GF Value Says OvervaluedOn June 22, 2026, Kiniksa Pharmaceuticals International PLC (KNSA) shares rose 3.5% today, bringing the current price to $57.13. The stock has shown strong perf
Zacks Investment Research·Jun 19, 2026
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep goingIf you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zacks Investment Research·Jun 18, 2026
New Strong Buy Stocks for June 18thTWFG, XPO, MUSA, FLYW and KNSA have been added to the Zacks Rank #1 (Strong Buy) List on June 18, 2026.
Zacks Investment Research·Jun 16, 2026
Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should KnowKiniksa Pharmaceuticals International, plc (KNSA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Peers Comparison
Key metrics vs top competitors for Kiniksa Pharmaceuticals, Ltd. (KNSA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $62.89 | $4.67B | 83.85 | 60.09% | 8.71% | 11.73% | — | |
| $5.16 | $1.27B | -19.85 | 22.09% | -13.58% | -38.11% | — | |
| $319.60 | $9.23B | -23.71 | -100% | — | -43.02% | — | |
| $28.92 | $2.91B | -8.79 | -4.26% | -156.36% | -68.97% | — | |
| $38.14 | $7.83B | -13.77 | — | — | -68.16% | — | |
| $2.99 | $487.53M | -1.82 | — | — | -131.58% | — |
Compare KNSA vs Peers
Kiniksa Pharmaceuticals, Ltd. (KNSA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KNSA SEC Filings & Documents
Kiniksa Pharmaceuticals, Ltd. (KNSA) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Jan 14, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when KNSA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KNSA Frequently Asked Questions
Kiniksa Pharmaceuticals, Ltd. (KNSA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Kiniksa Pharmaceuticals, Ltd.'s revenue?
Kiniksa Pharmaceuticals, Ltd. (KNSA) reported $754.0M in revenue for fiscal year 2025.
How fast is Kiniksa Pharmaceuticals, Ltd. growing?
Kiniksa Pharmaceuticals, Ltd. (KNSA) grew revenue by 60.1% over the past year. This is strong growth.
Is KNSA profitable?
Yes, Kiniksa Pharmaceuticals, Ltd. (KNSA) is profitable, generating $73.1M in net income for fiscal year 2025 (8.7% net margin).
Dividend & Returns
What is KNSA's return on equity?
Kiniksa Pharmaceuticals, Ltd. (KNSA) has a return on equity (ROE) of 11.7%. This is reasonable for most industries.
What is Kiniksa Pharmaceuticals, Ltd.'s free cash flow?
Kiniksa Pharmaceuticals, Ltd. (KNSA) generated $164.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.